Arkema S.A. manufactures and sells specialty chemicals and advanced materials worldwide.
Share Price & News
How has Arkema's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AKE is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AKE's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AKE exceeded the French Chemicals industry which returned 4.6% over the past year.
Return vs Market: AKE underperformed the French Market which returned 32.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Arkema's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWhat Type Of Shareholders Own The Most Number of Arkema S.A. (EPA:AKE) Shares?
4 weeks ago | Simply Wall StArkema (EPA:AKE) sheds 5.4% this week, as yearly returns fall more in line with earnings growth
1 month ago | Simply Wall StDoes Arkema (EPA:AKE) Have A Healthy Balance Sheet?
Arkema Fundamentals Summary
|AKE fundamental statistics|
Is AKE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AKE income statement (TTM)|
|Cost of Revenue||€6.71b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 10, 2021
|Earnings per share (EPS)||13.77|
|Net Profit Margin||12.35%|
How did AKE perform over the long term?See historical performance and comparison
2.2%Current Dividend Yield
Is Arkema undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AKE (€113.1) is trading below our estimate of fair value (€142.11)
Significantly Below Fair Value: AKE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AKE is good value based on its PE Ratio (8.1x) compared to the French Chemicals industry average (21.1x).
PE vs Market: AKE is good value based on its PE Ratio (8.1x) compared to the French market (21.2x).
Price to Earnings Growth Ratio
PEG Ratio: AKE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: AKE is good value based on its PB Ratio (1.5x) compared to the FR Chemicals industry average (1.6x).
How is Arkema forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKE's earnings are forecast to decline over the next 3 years (-16.8% per year).
Earnings vs Market: AKE's earnings are forecast to decline over the next 3 years (-16.8% per year).
High Growth Earnings: AKE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: AKE's revenue (2.9% per year) is forecast to grow slower than the French market (6.2% per year).
High Growth Revenue: AKE's revenue (2.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AKE's Return on Equity is forecast to be low in 3 years time (11.1%).
How has Arkema performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKE has a large one-off gain of €670.0M impacting its June 30 2021 financial results.
Growing Profit Margin: AKE's current net profit margins (12.4%) are higher than last year (4.4%).
Past Earnings Growth Analysis
Earnings Trend: AKE's earnings have grown by 3.8% per year over the past 5 years.
Accelerating Growth: AKE's earnings growth over the past year (188.2%) exceeds its 5-year average (3.8% per year).
Earnings vs Industry: AKE earnings growth over the past year (188.2%) exceeded the Chemicals industry 14.8%.
Return on Equity
High ROE: AKE's Return on Equity (18.8%) is considered low.
How is Arkema's financial position?
Financial Position Analysis
Short Term Liabilities: AKE's short term assets (€5.2B) exceed its short term liabilities (€2.1B).
Long Term Liabilities: AKE's short term assets (€5.2B) exceed its long term liabilities (€3.9B).
Debt to Equity History and Analysis
Debt Level: AKE's debt to equity ratio (49.2%) is considered high.
Reducing Debt: AKE's debt to equity ratio has reduced from 51.4% to 49.2% over the past 5 years.
Debt Coverage: AKE's debt is well covered by operating cash flow (39.8%).
Interest Coverage: AKE's interest payments on its debt are well covered by EBIT (15.2x coverage).
What is Arkema current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AKE's dividend (2.21%) is higher than the bottom 25% of dividend payers in the French market (1.27%).
High Dividend: AKE's dividend (2.21%) is low compared to the top 25% of dividend payers in the French market (3.88%).
Stability and Growth of Payments
Stable Dividend: AKE's dividends per share have been stable in the past 10 years.
Growing Dividend: AKE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (18.2%), AKE's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AKE's dividends in 3 years are forecast to be well covered by earnings (33% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thierry Le Henaff (58 yo)
Mr. Thierry Le Henaff has been Lead Independent Supervisory Board Member at Compagnie Générale des Établissements Michelin Société en commandite par actions since June 23, 2020. Mr. Le Henaff has been the...
CEO Compensation Analysis
Compensation vs Market: Thierry's total compensation ($USD4.64M) is above average for companies of similar size in the French market ($USD3.29M).
Compensation vs Earnings: Thierry's compensation has been consistent with company performance over the past year.
Experienced Management: AKE's management team is considered experienced (4.9 years average tenure).
Experienced Board: AKE's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Arkema S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Arkema S.A.
- Ticker: AKE
- Exchange: ENXTPA
- Founded: 2003
- Industry: Diversified Chemicals
- Sector: Materials
- Market Cap: €8.488b
- Shares outstanding: 75.05m
- Website: https://www.arkema.com
Number of Employees
- Arkema S.A.
- 420 rue d'Estienne d'Orves
Arkema S.A. manufactures and sells specialty chemicals and advanced materials worldwide. It operates in three segments: Adhesive Solutions, Advanced Materials, and Coating Solutions. Its products include a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/19 17:34|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.